NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-Shot gene therapy could change wet AMD treatment
Disease control Recruiting nowThis study tests a new gene therapy called LX102 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment is given as a single injection under the retina and is compared to standard eye injections. The goal is to see if LX102 can i…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated May 17, 2026 03:57 UTC
-
One shot could replace dozens: gene therapy trial for blinding eye disease
Disease control Recruiting nowThis phase 3 trial tests a single injection of 4D-150 gene therapy in 480 adults with wet age-related macular degeneration (nAMD). The goal is to see if one treatment can control the disease and reduce the need for frequent anti-VEGF eye injections. Participants receive either 4D…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
One-shot gene therapy could cut eye injections for wet AMD
Disease control Recruiting nowThis phase 3 study tests a single injection of Ixo-vec gene therapy in 284 people with wet age-related macular degeneration (nAMD). The goal is to see if Ixo-vec can maintain or improve vision as well as standard aflibercept injections, but with fewer follow-up injections. Partic…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
New eye implant could cut frequent injections for wet AMD patients
Disease control Recruiting nowThis study tests an implant called AR-14034 that slowly releases medicine into the eye to treat wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if this implant can safely control the disease with fewer treatments compared to standard…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE1, PHASE2 • Sponsor: Alcon Research • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
One shot to save sight? gene therapy trial aims to end frequent eye injections for wet AMD
Disease control Recruiting nowThis phase 3 study tests a single injection of a gene therapy called Ixo-vec for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if this one-time treatment can maintain or improve vision as well as standard care (afliberc…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC